Compare EPAM Systems Inc (EPAM) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Johnson & Johnson — how do they compare? EPAM Systems Inc trades at $113.34 (market cap $5.87B), while Johnson & Johnson trades at $260.72 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 105.3× EPAM Systems Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Johnson & Johnson for 129 Days on average.
| EPAM | JNJ | |
|---|---|---|
Market Cap | $5.87B | $618.09B |
Volume | 847,420 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $221.40 | $278.43 |
52-Week Low | $76.04 | $186.00 |
Typical Hold Time | 37 Days | 129 Days |
Enterprise Value | $5.24B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $113.54, up 4.82% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $119 suggest upside potential. The company reported $5.46B in 2025 revenue, with a net income margin of 7.15%, while maintaining solid cash flow from operations of $654.93M.
The outlook is positive, driven by AI-native revenue growth exceeding 11% and activist shareholder pressure for buybacks. Risks include slower North American growth and competitive pressures in digital transformation services. The stock's current valuation at a P/E of 15.45 appears reasonable relative to earnings growth prospects.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
